CN-21 RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825

BACKGROUND: TMZ is well tolerated with a relatively low incidence of myelotoxicity, which can nonetheless result in treatment delays or death. Our goal was to evaluate risk and validate prediction models in newly diagnosed patients treated with TMZ +/- bevacizumab (BEV). METHODS: Models (from recurr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Zhou, Renke, Scheurer, Michael, Vera-Bolanos, Elizabeth, Gilbert, Mark, Bondy, Melissa, Sulman, Eric, Hilsenbeck, Sue, Wendland, Merideth, Brachman, David, Roof, Kevin, Komaki, Ritsuko, Deutsch, Melvin, Andrews, David, Anderson, Bethany, Lee, R. Jeffrey, Pugh, Stephanie, Armstrong, Terri
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218016/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou243.21
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky